Eric G. Devine, PhD
Assistant Professor
Boston University Chobanian & Avedisian School of Medicine
Psychiatry
General Psychiatry

PhD, Bowling Green State University
MA, Bowling Green State University
BA, University of Wisconsin–Milwaukee



Eric Devine is the director of the Clinical Studies Unit in the Department of Psychiatry at Boston Medical Center. Dr. Devine serves as Vice-Chair for the Boston Medical Center and Boston University Medical Campus Institutional Review Board, and he is the Director of the IRB Internship training program. He teaches addiction treatment courses for the Mental Health Counseling and Behavioral Medicine Program at Chobanian and Avedisian School of Medicine, and also for the BU School of Social Work Professional Education Program. Dr. Devine is a member of the Motivational Interviewing Network of Trainers (MINT). He has participated in numerous NIAAA and NIDA-funded multi-site trials testing medications for the treatment of substance use disorders and has had a role in two SAMHSA-funded grants focused on training and dissemination of SBIRT. Dr. Devine also had a role in the development of psychosocial treatments for addiction and has co-authored several treatment manuals and online behavioral platforms for use in multi-site trials testing medications for substance use disorders.

Special Interests: Medication development, clinical trials, psychosocial treatments for substance use disorder, motivational interviewing, cognitive behavioral therapy, universal screening for substance use, ethics of human subjects' research, and manualized treatment approaches for substance use disorders.


Mood Management Versus Mood Tolerance in Alcohol Treatment
04/01/2000 - 03/31/2004 (Co-PI)
NIH/National Institute on Alcohol Abuse and Alcoholism
5 R03 AA12210 02


NCIG-7 NIAAA Randomized, Double Blind, Placebo-Controlled Trial of the Efficacy of Intranasal Oxytocin for the Treatment of Alcohol Use Disorder
02/17/2022 - 06/30/2024 (PI)
Fast Track Drugs and Biologics National Institute o

Clinical Research Sites for the NIAAA Medications Development Clinical Investigations Network for the Treatment of Alcohol Use Disorder
03/15/2021 - 03/14/2024 (PI)
National Institute of Child Health and Human Development/NIH/DHHS

The Effects of the Histamine-3 Receptor Inverse Agonist Pitolisant on Alcohol Self-Administration in Heavy Drinkers
09/20/2020 - 08/30/2023 (PI)
National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS
1R21AA028864-01

The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy Drinkers
09/01/2019 - 08/31/2021 (PI)
National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS
5R21AA027332-02

R21 - Lacosamide effects on alcohol self administration and craving in heavy drinkers
09/01/2018 - 08/31/2021 (PI)
National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS
5R21AA026389-02

Wearable Noninvasive Blood Alcohol Monitor
08/01/2019 - 09/30/2020 (PI)
KWJ Engineering, Inc. National Institute o
2R44AA024651-02

Phase 2, Multi-Center Trial of Lorcaserin in the Treatment of Cocaine Use Disorder
04/01/2017 - 04/30/2019 (PI)
National Institute on Drug Abuse/NIH/DHHS

NCIG-007 CLINICAL STUDY
10/01/2017 - 02/28/2018 (PI)
Fast Track Drugs and Biologics National Institute o

NCIG-006, Randomized, Double Blind, Placebo-Controlled Trial of the Safety and Efficacy of …
04/01/2015 - 09/19/2017 (PI)
Fast Track Drugs and Biologics NIH-NIAAA


Title


Yr Title Project-Sub Proj Pubs
2021 The Effects of the Histamine-3 Receptor Inverse Agonist Pitolisant on Alcohol Self-Administration in Heavy Drinkers 5R21AA028864-02
2020 The Effects of the Histamine-3 Receptor Inverse Agonist Pitolisant on Alcohol Self-Administration in Heavy Drinkers 1R21AA028864-01
2019 The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy Drinkers 5R21AA027332-02
2018 The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy Drinkers 1R21AA027332-01
2018 Lacosamide effects on alcohol self administration and craving in heavy drinkers 5R21AA026389-02
2017 Lacosamide effects on alcohol self administration and craving in heavy drinkers 1R21AA026389-01

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Devine EG, Pingitore AM, Margiotta KN, Hadaway NA, Reid K, Peebles K, Hyun JW. Frequency of concealment, fabrication and falsification of study data by deceptive subjects. Contemp Clin Trials Commun. 2021 Mar; 21:100713. PMID: 33604482; PMCID: PMC7876535; DOI: 10.1016/j.conctc.2021.100713;
     
  2. Gewandter JS, Dworkin RH, Turk DC, Devine EG, Hewitt D, Jensen MP, Katz NP, Kirkwood AA, Malamut R, Markman JD, Vrijens B, Burke L, Campbell JN, Carr DB, Conaghan PG, Cowan P, Doyle MK, Edwards RR, Evans SR, Farrar JT, Freeman R, Gilron I, Juge D, Kerns RD, Kopecky EA, McDermott MP, Niebler G, Patel KV, Rauck R, Rice ASC, Rowbotham M, Sessler NE, Simon LS, Singla N, Skljarevski V, Tockarshewsky T, Vanhove GF, Wasan AD, Witter J. Improving Study Conduct and Data Quality in Clinical Trials of Chronic Pain Treatments: IMMPACT Recommendations. J Pain. 2020 Sep - Oct; 21(9-10):931-942. PMID: 31843583; PMCID: PMC7292738; DOI: 10.1016/j.jpain.2019.12.003;
     
  3. Falk DE, Ryan ML, Fertig JB, Devine EG, Cruz R, Brown ES, Burns H, Salloum IM, Newport DJ, Mendelson J, Galloway G, Kampman K, Brooks C, Green AI, Brunette MF, Rosenthal RN, Dunn KE, Strain EC, Ray L, Shoptaw S, Ait-Daoud Tiouririne N, Gunderson EW, Ransom J, Scott C, Leggio L, Caras S, Mason BJ, Litten RZ. Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial Assessing Efficacy and Safety. Alcohol Clin Exp Res. 2019 01; 43(1):158-169.View Related Profiles. PMID: 30403402; PMCID: PMC6317996; DOI: 10.1111/acer.13917;
     
  4. Devine EG, Peebles KR, Martini V. Strategies to exclude subjects who conceal and fabricate information when enrolling in clinical trials. Contemp Clin Trials Commun. 2017 Mar; 5:67-71. PMID: 29740622; PMCID: PMC5936691; DOI: 10.1016/j.conctc.2016.12.005;
     
  5. Devine EG, Ryan ML, Falk DE, Fertig JB, Litten RZ. An exploratory evaluation of Take Control: A novel computer-delivered behavioral platform for placebo-controlled pharmacotherapy trials for alcohol use disorder. Contemp Clin Trials. 2016 Sep; 50:178-85. PMID: 27521807; PMCID: PMC5065069; DOI: 10.1016/j.cct.2016.08.006;
     
  6. Knapp CM, Ciraulo DA, Sarid-Segal O, Richardson MA, Devine E, Streeter CC, Oscar-Berman M, Surprise C, Colaneri L, Putnam M, Waters M, Richambault C. Zonisamide, topiramate, and levetiracetam: efficacy and neuropsychological effects in alcohol use disorders. J Clin Psychopharmacol. 2015 Feb; 35(1):34-42.View Related Profiles. PMID: 25427171; PMCID: PMC4276485; DOI: 10.1097/JCP.0000000000000246;
     
  7. Devine, E. G., Knapp CM, Sarid-Segal, O, O’Keefe SO, Wardell C, Baskett M, Pecchia A, Ferrell, K, & Ciraulo, DA . Payment expectations for research participation among subjects who tell the truth, subjects who conceal information, and subjects who fabricate information. Contemporary Clinical Trials. 2014; (41):55-61.
  8. Devine EG, Knapp CM, Sarid-Segal O, O'Keefe SM, Wardell C, Baskett M, Pecchia A, Ferrell K, Ciraulo DA. Payment expectations for research participation among subjects who tell the truth, subjects who conceal information, and subjects who fabricate information. Contemp Clin Trials. 2015 Mar; 41:55-61.View Related Profiles. PMID: 25530307; PMCID: PMC5065068; DOI: 10.1016/j.cct.2014.12.004;
     
  9. DeMartini KS, Devine EG, DiClemente CC, Martin DJ, Ray LA, O'Malley SS. Predictors of pretreatment commitment to abstinence: results from the COMBINE study. J Stud Alcohol Drugs. 2014 May; 75(3):438-46. PMID: 24766756; PMCID: PMC4002857; DOI: 10.15288/jsad.2014.75.438;
     
  10. Ciraulo DA, Barlow DH, Gulliver SB, Farchione T, Morissette SB, Kamholz BW, Eisenmenger K, Brown B, Devine E, Brown TA, Knapp CM. The effects of venlafaxine and cognitive behavioral therapy alone and combined in the treatment of co-morbid alcohol use-anxiety disorders. Behav Res Ther. 2013 Nov; 51(11):729-35.View Related Profiles. PMID: 24055681; PMCID: PMC3981550; DOI: 10.1016/j.brat.2013.08.003;
     
Showing 10 of 21 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 21 publications over 14 distinct years, with a maximum of 3 publications in 2014

YearPublications
19961
20002
20051
20082
20091
20101
20122
20132
20143
20151
20162
20181
20191
20211

In addition to these self-described keywords below, a list of MeSH based concepts is available here.

cognitive behavioral therapy
motivational interviewing
treatment research
Contact for Mentoring:

720 Harrison Ave
Boston MA 02118
Google Map

617.638.7888
Download vCard

Devine's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
See all (107) concept(s)
_
Media Mentions
_
Co-Authors
See all (3) people
_
Similar People
See all (60) people
_
Same Department
Search Department